Morningstar

Damien Conover, CFA

Damien Conover, CFA, is director of equity research, North America, for Morningstar.

More From Damien Conover

Drug and biotech industries pricing in the risk of policy changes in the U.S., but we don't think there will be a big regulatory impact.
Damien Conover, CFA

The warnings put pressure on key drugs for AbbVie, Pfizer, and Eli Lilly, but we don’t see any major fair value estimate impacts.
Damien Conover, CFA

The new CEO is likely focused on continuing the industry-leading innovative strategy.
Damien Conover, CFA

We continue to view the stock as undervalued with the market not appreciating Merck’s strong immuno-oncology position and developing pipeline, key areas that reinforce our wide moat rating.
Damien Conover, CFA

The company continues to innovate across segments, adding support to its wide moat.
Damien Conover, CFA

We continue to view AbbVie as fairly valued with a good appreciation of new drugs partially offsetting the likely U.S. generic pressure to Humira.
Damien Conover, CFA

More About Damien Conover

Damien Conover, CFA, is director of equity research, North America, for Morningstar.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

Sponsor Center